Retatrutide: Eli Lilly Weight Loss Drug Shows Promise in Late-Stage Trial
Eli lilly’s Retatrutide shows Promising Weight Loss and Arthritis Relief
Eli Lilly on Thursday announced positive results from a late-stage trial of its next-generation obesity drug, retatrutide. The drug demonstrated significant weight loss and reduction in knee arthritis pain.
Key Trial Results
- Average Weight Loss (All Participants): 23.7% at 68 weeks.
- Average Weight Loss (Patients Remaining on Drug): 28.7% at 68 weeks.
- Knee osteoarthritis Pain Reduction (All Participants): Up to 62.6% based on a widely used survey.
- Patients Free from Knee Pain: More than one in eight patients.
Retatrutide vs. Existing Treatments
Retatrutide works differently from existing weight loss injections and appears to be more effective. Eli Lilly views it as a key component of its future obesity portfolio, alongside Zepbound and an upcoming pill.
Market Implications
The success of retatrutide is vital for Eli Lilly to maintain its market leadership in the booming weight loss and diabetes drug market, currently competing with Novo Nordisk. analysts estimate this market could reach $100 billion by the 2030s.
Trial Data Breakdown
| Metric | Result |
|---|---|
| Average Weight Loss (All Participants) | 23.7% (at 68 weeks) |
| Average Weight Loss (Patients Remaining on Drug) | 28.7% (at 68 weeks) |
| Knee Osteoarthritis Pain Reduction (All Participants) | Up to 62.6% |